- Integration reaches over 4,500 clinicians across 1,000 community-based cancer care locations.
- Streamlined workflow enables direct ordering and review of test results within EMR.
- Enhanced accessibility to MRD testing for community oncology practices where majority of Americans receive cancer care.
Adaptive Biotechnologies (ADPT, Financial) has announced a strategic partnership with Flatiron Health to integrate its clonoSEQ® test for measurable residual disease (MRD) into the OncoEMR® platform. This integration will simplify access and enhance the workflow for over 4,500 clinicians across 1,000 community-based cancer care locations in the United States by allowing direct ordering and reviewing of clonoSEQ MRD testing results within the Electronic Medical Record (EMR) system.
Effective July 1, 2025, healthcare providers will be able to leverage this integration to gain real-time insights into patient disease status, particularly for blood cancer patients. The clonoSEQ test is pivotal in detecting small numbers of cancer cells that may persist during and after treatment, serving as a crucial predictor of patient outcomes.
This development marks a significant commercial expansion for Adaptive Biotechnologies, as the integration is strategically set to remove previous workflow inefficiencies. By embedding diagnostic capabilities directly into OncoEMR’s Molecular Profiling Integration platform, Adaptive has streamlined access to critical MRD testing, facilitating personalized treatment decisions based on real-time disease data.
In addition, the partnership embodies Adaptive Biotechnologies’ focus on reducing barriers to clonoSEQ adoption, aiming to enhance patient care experiences by ensuring clinicians can easily access and apply critical MRD insights. The integration will also bolster Adaptive’s position against emerging MRD testing alternatives, accelerating test volume growth through its EMR-integrated approach.
clonoSEQ will continue to be accessible to providers outside the Flatiron network through other EMR integrations and Adaptive’s online diagnostic portal, ensuring wide-reaching availability of the critical MRD assessment tool.
